Naif Alsiwiehri*

Department of Clinical Laboratory Science, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia

*Corresponding Author:Naif Alsiwiehri, Department of Clinical Laboratory Science, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.

Received: March 17, 2025; Published: April 10, 2025

Abstract

Background: Human Cytomegalovirus (HCMV) is a widespread herpesvirus that remains latent in the body of healthy individuals and reactivates during the weakness of the immune system. This virus has been implicated in many malignancies and has been found to cause graft rejections and several other complications. This study aimed to determine the prevalence of HCMV-DNA viremia among breast cancer, and associate it the type and grade of the cancer.

Methods: 88-female patients with confirmed breast cancer have been included in the study. Blood samples (5 ml) were collected from patients at armed forces hospitals from January 2023 to March 2024. Detection of CMV-DNA is achieved through molecular methods, specifically using quantitative PCR (qPCR) with the COBAS 5800 system. Statistical analysis was performed by Chi-square test of independence with P value significant < 0.05.

Results: HCMV-DNA detected in 11.3% (10:88) of the cases. Among these, 9 cases were ductal carcinoma, and single was medullary carcinoma. HCMV prevalence was highest in grade I tumour (6 cases), then by grade II (2 cases), and grade III (2 cases). Most cases exhibited low viral load (8:10), while only two cases has medium viral load.

Conclusion: Our Results suggests a low prevalence of HCMV-DNA viremia among our study participants, most cases detected in ductal carcinoma, and early-stage tumour. Further research is essential and required to classify HCMV role in breast cancer progression and prognosis.

 Keywords: CMV; HCMV-DNA Viremia; Immune System; Breast Cancer

References

1. Xu Hangcheng and Binghe Xu. “Breast cancer: Epidemiology, risk factors and screening”. Chinese Journal of Cancer Research6 (2023): 565.
2. Obeagu Emmanuel Ifeanyi and Getrude Uzoma Obeagu. “Breast cancer: A review of risk factors and diagnosis”. Medicine3 (2024): e36905.
3. M Almehmadi., et al. “CD56+ T cells are increased in kidney transplant patients following cytomegalovirus infection”. Transplant Infectious Disease 17 (2015): 518-526.
4. FG Frantzeskaki., et al. “Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: Incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers”. Journal of Critical Care 30 (2015): 276-281.
5. Touma Joel., et al. “Human cytomegalovirus protein expression is correlated with shorter overall survival in breast cancer patients: a cohort study”. Viruses 3 (2023): 732.
6. T Al-Tweigeri., et al. “Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer”. Journal of Oncology 2021 (2021).
7. CS Cobbs., et al. “Human cytomegalovirus infection and expression in human malignant glioma”. Cancer Research 62 (2002): 3347-3350.
8. MV Dioverti., et al. “Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease”. Open Forum Infectious Diseases 4 (2017): ofx143.
9. G Herbein and A Kumar. “The oncogenic potential of human cytomegalovirus and breast cancer”. Frontiers in Oncology 4 (2014): 107215.
10. L Lamara Mahammed., et al. “High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection”. Transplant Immunology (2025).
11. AP Limaye., et al. “Cytomegalovirus reactivation in critically ill immunocompetent patients”. JAMA 300 (2008): 413-422.
12. L Nobre., et al. “Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions”. Elife 8 (2019).
13. A Peppercorn., et al. “Reactivation of cytomegalovirus infection in critically ill immunocompetent patients”. JAMA 300 (2008): 2367-2368.
14. D Utrera-Barillas., et al. “Is human cytomegalovirus associated with breast cancer progression?”. Infectious Agent Cancer 8 (2013): 1-5.
15. C Yu., et al. “Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential”. Frontiers in Cellular and Infection Microbiology 13 (2023): 1202138.
16. Richardson AK., et al. “Breast cancer and cytomegalovirus”. Clinical and Translational Oncology 22 (2020): 585-602.
17. Spencer JV., et al. “Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status”. Breast Cancer Research Treatment 208 (2024): 631-641.

Citation

Citation: Naif Alsiwiehri. “Prevalence of Human Cytomegalovirus in Breast Cancer Patients: A Cross-Sectional Study”.Acta Scientific Medical Sciences 9.5 (2025): 70-73.

Copyright

Copyright: © 2025 Naif Alsiwiehri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.